<DOC>
	<DOCNO>NCT00350792</DOCNO>
	<brief_summary>A phase II study evaluate efficacy safety profile combination Pemetrexed Carboplatin elderly patient advance non-small cell lung cancer</brief_summary>
	<brief_title>Pemetrexed/Carboplatin Non-Small Cell Lung Cancer ( NSCLC ) Elderly Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Pathologically confirm Non Small Cell Lung Cancer Stage IIIb ( amenable radiotherapy treatment ) Stage IV No previous chemotherapy lung cancer Men woman &gt; = 70 year At least one unidimensionally measurable lesion ( Response Evaluation Criteria In Solid Tumors [ RECIST ] criterion ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Treatment within last 30 day drug receive regulatory approval Serious systemic disorder Inability discontinue administration aspirin antiinflammatory non steroid Concurrent administration antitumor therapy Brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>